The FDA has approved a new drug called Adempas (riociguat) for two types of high blood pressure in the lungs. The first is chronic thromboembolic pulmonary hypertension (CTEPH), which can occur after blood clots in the lungs. The second is pulmonary arterial hypertension (PAH), a condition where the arteries in the lungs narrow. Adempas is a pill taken three times a day. It works by helping blood vessels relax, which lowers blood pressure in the lungs and makes it easier for the heart to pump blood.
This approval is for patients with CTEPH who cannot have surgery or whose condition remains after surgery. For PAH, it is for patients with mild to moderate symptoms (WHO functional class II–III). In studies, patients taking Adempas were able to walk farther and felt better. The drug can be used alone or with other PAH medicines.
Adempas is not a cure. It is a treatment that may improve symptoms and quality of life. The starting dose is 1 mg three times a day, and your doctor may adjust it based on how you tolerate it. Common side effects include headache, dizziness, and upset stomach.
If you have pulmonary hypertension, talk to your doctor about whether Adempas might be right for you. Do not stop or change your current medicines without medical advice.